Home > Insider Trading > Filing (0000950170-24-118424)

Filing Details

Accession Number:: 0000950170-24-118424
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-10-29 18:33:30
Reporting Period:: 2024-10-27

Accepted Time:: 2024-10-29 18:33:30
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1609809	Seres Therapeutics Inc.	MCRB	Pharmaceutical Preparations (2834)	274326290

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1808592	Lisa Moltke Von	C/O Seres Therapeutics, Inc. 101 Cambridge Park Drive Cambridge MA 02140	See Remarks	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-10-27	13,744	$0.00	34,757	No	4	M	Direct
Common Stock	Disposition	2024-10-28	4,334	$0.69	30,423	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2024-10-27	13,744	$0.00	13,744	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	M	Direct

Footnotes

On February 3, 2023, the reporting person was granted an award of 27,489 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,745 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 13,744 RSUs vested and settled on October 27, 2024, the date that was eighteen months from the Initial Milestone Date.
Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on July 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.69 to $ 0.7011, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.